Download MendeleyIdentification of potent inhibitors of the sortilin-progranulin interaction.
Stachel, S.J., Ginnetti, A.T., Johnson, S.A., Cramer, P., Wang, Y., Bukhtiyarova, M., Krosky, D., Stump, C., Hurzy, D.M., Schlegel, K.A., Cooke, A.J., Allen, S., O'Donnell, G., Ziebell, M., Parthasarathy, G., Getty, K.L., Ho, T., Ou, Y., Jovanovska, A., Carroll, S.S., Pausch, M., Lumb, K., Mosser, S.D., Voleti, B., Klein, D.J., Soisson, S.M., Zerbinatti, C., Coleman, P.J.(2020) Bioorg Med Chem Lett 30: 127403-127403
- PubMed: 32738972 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2020.127403
- Primary Citation Related Structures:
6X3L, 6X48, 6X4H - PubMed Abstract:
High-throughput screening methods have been used to identify two novel series of inhibitors that disrupt progranulin binding to sortilin. Exploration of structure-activity relationships (SAR) resulted in compounds with sufficient potency and physicochemical properties to enable co-crystallization with sortilin. These co-crystal structures supported observed SAR trends and provided guidance for additional avenues for designing compounds with additional interactions within the binding site.
- Department of Medicinal Chemistry, Merck & Co. Inc., PO Box 4, West Point, PA 19486, USA. Electronic address: shawn_stachel@merck.com.
Organizational Affiliation:
